From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.

Gilead HQ
Gilead undertakes a host of R&D efforts to keep top position in HIV • Source: Shutterstock

Gilead Sciences, Inc. secured the dominant position in HIV therapy years ago, but maintaining that lead has taken an aggressive research and development effort aimed at optimizing current therapy for patients infected with the virus and also preventing infections in at-risk populations. Coming out of the recent International AIDS Conference, two of Gilead’s top HIV researchers reviewed the company’s current research priorities.

Jared Baeten, Gilead’s VP for HIV clinical research, came to Gilead into October 2020 after more than 16 years at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.